Sendai Virus

Overview and Taxonomy of Sendai Virus (Murine Parainfluenza Virus Type 1)

Sendai virus (SeV), historically and taxonomically designated as murine parainfluenza virus type 1 (mPIV-1), represents a prototypical member of the family Paramyxoviridae, genus Respirovirus. First isolated in Sendai, Japan, in 1953 during an outbreak of fatal pneumonitis in laboratory mice, the virus has since become one of the most extensively studied model systems in molecular virology, viral immunology, and respiratory pathogenesis [10]. Its classification within the Respirovirus genus places it alongside human parainfluenza virus type 1 (hPIV-1) and type 3 (hPIV-3), with which it shares significant structural, genomic, and functional homology. Indeed, the close antigenic and genetic relationship between SeV and hPIV-1 has been the foundation for its development as a Jennerian vaccine vector, wherein a murine virus is used to protect against its human counterpart [2, 12]. This taxonomic positioning is not merely a matter of nomenclature; it underpins the virus’s utility as a surrogate model for human respiratory disease and as a platform for vaccine and gene therapy vector development.

At the molecular level, SeV is an enveloped, negative-sense, single-stranded RNA virus with a non-segmented genome of approximately 15.4 kilobases. The genome encodes six structural proteins in the canonical order 3′-N-P-M-F-HN-L-5′, where N is the nucleoprotein, P is the phosphoprotein, M is the matrix protein, F is the fusion glycoprotein, HN is the hemagglutinin-neuraminidase glycoprotein, and L is the large RNA-dependent RNA polymerase [10, 15]. The HN and F glycoproteins are the primary determinants of host cell tropism and entry. HN binds to sialic acid-containing receptors on the host cell surface, while F mediates pH-independent fusion of the viral envelope with the host cell plasma membrane at neutral pH, a hallmark of paramyxovirus entry. This fusion mechanism is critical for direct cell-to-cell spread and syncytium formation, a cytopathic effect commonly observed in SeV-infected cell cultures. The virus replicates entirely in the cytoplasm, a feature that eliminates the risk of genomic integration, a property that has been exploited for the development of safe, non-integrating gene therapy and induced pluripotent stem cell (iPSC) reprogramming vectors [5, 6, 10, 11]. The cytoplasmic replication cycle is orchestrated by the viral ribonucleoprotein (vRNP) complex, consisting of the genomic RNA tightly encapsidated by the N protein, along with the P and L proteins. Recent live-cell imaging studies have revealed that vRNPs are trafficked along microtubules via association with Rab11a-positive recycling endosomes, a process essential for efficient transport to the plasma membrane assembly sites [15]. This vesicular trafficking mechanism highlights the sophisticated interplay between the virus and the host cellular machinery, a theme that recurs throughout SeV biology.

The natural host range of SeV is primarily rodents, particularly laboratory mice, in which it causes a highly contagious respiratory infection characterized by bronchiolitis and interstitial pneumonia. In immunocompetent adult mice, infection is typically acute and self-limiting, with viral clearance mediated by a robust adaptive immune response involving both cytotoxic T lymphocytes (CTLs) and virus-specific antibodies [13, 16]. However, in neonatal or immunocompromised mice, SeV can cause lethal pneumonitis, making it a valuable model for studying the pathogenesis of severe respiratory viral infections. The virus is not considered a natural pathogen of humans, although serological evidence of cross-reactive antibodies to SeV has been reported in human populations, likely due to prior exposure to hPIV-1. This lack of human pathogenicity, combined with its ability to infect a wide range of mammalian cells, has made SeV an attractive vector for human vaccine development. Notably, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have recognized the potential of paramyxovirus-based vectors for respiratory virus vaccines, and SeV-based candidates have been evaluated in clinical trials for human parainfluenza virus type 1 and respiratory syncytial virus (RSV) [2, 12].

The taxonomic relationship between SeV and hPIV-1 is of particular interest from both evolutionary and translational perspectives. SeV is considered the murine counterpart of hPIV-1, and the two viruses share approximately 70–75% nucleotide sequence identity in their HN and F genes. This genetic similarity translates into antigenic cross-reactivity, which forms the basis for the Jennerian vaccine approach. In preclinical studies, intranasal administration of SeV to African green monkeys (AGM) elicited robust humoral and cellular immune responses that conferred complete protection against subsequent challenge with hPIV-1 [2, 12]. Furthermore, recombinant SeV vectors engineered to express the RSV fusion protein (SeVRSV) have demonstrated dual protection against both hPIV-1 and RSV in AGM models, with no evidence of enhanced respiratory disease, a critical safety concern that plagued early RSV vaccine candidates [12]. The safety profile of SeV-based vaccines has been further supported by phase I clinical trials in healthy adults, where intranasal administration of SeVRSV was well-tolerated, with only mild, transient adverse events comparable to placebo [2]. These findings underscore the potential of SeV as a safe and immunogenic vector platform for human use.

Beyond its role in vaccinology, SeV has emerged as a versatile tool in gene therapy and regenerative medicine. The virus’s cytoplasmic replication cycle, which avoids any DNA intermediate, eliminates the risk of insertional mutagenesis, a major safety concern associated with retroviral and lentiviral vectors. This property has been harnessed for the generation of integration-free iPSCs, where SeV vectors carrying reprogramming factors (Oct4, Sox2, Klf4, and c-Myc) can efficiently reprogram somatic cells without altering the host genome [5, 8, 11]. The development of defective and persistent SeV vectors (SeVdp) has further refined this approach, enabling sustained transgene expression for the duration of reprogramming while allowing for subsequent clearance of the viral RNA through siRNA-mediated interference or antibody-based negative selection targeting the HN surface protein [14]. This technology has been successfully applied to generate transgene-free human iPSCs from peripheral blood mononuclear cells and fibroblasts, with differentiation potential spanning all three germ layers [5, 8, 11]. The efficiency of SeV-mediated reprogramming, often exceeding 1% of transduced cells, is remarkably high compared to other non-integrating methods, making it a preferred platform for clinical-grade iPSC production.

The oncolytic potential of SeV represents another frontier in its translational application. Unlike many oncolytic viruses that rely on selective replication in cancer cells, SeV-based virotherapy exploits unique anticancer mechanisms, including the induction of potent innate immune responses and the direct lysis of tumor cells [4, 7]. In a pilot study involving canine patients with mast cell tumors, intratumoral and peritumoral injections of SeV resulted in complete responses in five out of six dogs, with durable remission lasting 2–3 years [4]. The virus was well-tolerated, with only minor transitory side effects, and demonstrated efficacy even in advanced disease stages with metastatic spread. These findings are particularly noteworthy given the World Organisation for Animal Health (WOAH) recognition of the need for novel therapeutic approaches in veterinary oncology. The oncolytic mechanism is thought to involve both direct viral replication in tumor cells and the activation of antitumor immune responses, including the recruitment of dendritic cells and the induction of pro-inflammatory cytokines [7, 9]. The immunostimulatory properties of SeV are further amplified by defective viral genomes (DVGs), which are naturally generated during viral replication and serve as potent agonists of the RIG-I-like receptor pathway [3, 9]. DVG-enriched SeV preparations have been shown to induce high levels of interferon-β and pro-inflammatory cytokines, enhancing dendritic cell maturation and T cell activation [9]. This dual mechanism, direct oncolysis coupled with immune activation, positions SeV as a promising candidate for cancer immunotherapy.

The epidemiological significance of SeV extends beyond laboratory rodents. Recent metagenomic surveys have identified SeV sequences in Malayan pangolins (Manis javanica), an endangered species under urgent conservation pressure [1]. This discovery, the first report of SeV in pangolins, expands our understanding of the virus’s host range and raises questions about its potential for cross-species transmission. The detection of SeV alongside coronaviruses in pangolin samples suggests that these animals may serve as reservoirs for multiple respiratory viruses, with implications for both wildlife conservation and zoonotic risk assessment [1]. While SeV is not currently classified as a zoonotic pathogen by the CDC or the Food and Agriculture Organization (FAO), the ability of paramyxoviruses to jump species boundaries, exemplified by the emergence of Nipah and Hendra viruses, underscores the importance of ongoing surveillance. The pangolin findings highlight the need for a One Health approach to monitor viral diversity in wildlife, particularly in species that are trafficked or in close contact with humans.

In summary, Sendai virus occupies a unique niche in virology, serving simultaneously as a model pathogen for basic research, a platform for vaccine and gene therapy development, and a potential oncolytic agent. Its taxonomic classification as murine parainfluenza virus type 1 within the Respirovirus genus provides the framework for understanding its biology, host range, and translational potential. The virus’s cytoplasmic replication, lack of genomic integration, and ability to induce robust mucosal immunity make it an ideal vector for respiratory vaccines and regenerative medicine. As research continues to uncover new aspects of SeV biology, from its vesicular trafficking mechanisms to its immunostimulatory DVGs, the virus will undoubtedly remain at the forefront of virological innovation.

Molecular Pathogenesis and Host Immune Evasion by Sendai Virus

Sendai virus (SeV), a prototypical member of the Paramyxoviridae family within the genus Respirovirus, represents a paradigm for understanding the intricate molecular interplay between a non-segmented negative-sense RNA virus and its mammalian host. Unlike many cytolytic viruses that rely on genomic integration or nuclear replication, SeV executes its entire life cycle within the cytoplasm, a constraint that has driven the evolution of sophisticated mechanisms to usurp host cell machinery while simultaneously dismantling the host’s antiviral defenses. The molecular pathogenesis of SeV is not a narrative of brute-force cellular destruction, but rather a highly choreographed process of subversion, latency, and strategic immune modulation, often leading to persistent infections that can serve as a reservoir for zoonotic or cross-species transmission [1, 10]. This section dissects the molecular events from viral entry to assembly, with a particular focus on the virus’s capacity to evade the host immune system, a duality that makes SeV both a formidable pathogen in murine models and a promising vector for vaccine development and oncolytic therapy.

Molecular Mechanisms of Viral Replication and Intracellular Trafficking

The pathogenesis of SeV begins at the molecular level with the delivery of its negative-sense RNA genome into the host cytoplasm. The viral ribonucleocapsid (vRNP) is not a passive cargo; rather, its trafficking to the sites of replication and assembly is a critical determinant of viral fitness. Real-time imaging studies using a recombinant SeV expressing an L-protein fused to enhanced green fluorescent protein (eGFP) have revealed that vRNP movement is not stochastic but is instead a highly directed, saltatory process that depends entirely on the host’s microtubule network [15]. The disruption of microtubules with nocodazole significantly restricts vRNP translocation and impairs progeny virion production without affecting viral protein synthesis, underscoring that the cytoskeleton is an essential cofactor for the virus [15].

However, the mechanism by which SeV harnasses this transport machinery is notably indirect. Rather than associating directly with motor proteins, vRNPs are co-opted into the cellular endocytic recycling pathway. Evidence demonstrates that vRNPs co-localize with Rab11a, a small GTPase that regulates recycling endosome trafficking. Video microscopy has captured the simultaneous movement of L-eGFP and Rab11a-mRFP in live cells, confirming that these intracellular vesicles serve as the physical vehicle for vRNP transport to the plasma membrane [15]. Furthermore, the vRNPs move concomitantly with recycling transferrin, a canonical marker of this pathway [15]. This exploitation of the host’s vesicular trafficking network provides the virus with a stable, protected microenvironment for genome transport, shielding the RNA from cytoplasmic sensors while ensuring its delivery to assembly sites. This molecular hijacking of the recycling endosome is a key pathogenic strategy, as it allows for efficient production of progeny virions, directly contributing to the severity of respiratory disease in susceptible hosts.

Innate Immune Evasion: The Role of the C Protein and Defective Viral Genomes

The cytoplasmic replication of SeV poses an inherent risk of detection by host pattern recognition receptors (PRRs), particularly the RIG-I-like receptors (RLRs) that surveil for non-self RNA. To counter this, SeV has evolved a multi-layered strategy of innate immune evasion. A crucial player is the accessory C protein, expressed from overlapping reading frames of the P gene. The C protein is a potent antagonist of the interferon (IFN) signaling cascade, directly interfering with the activation of IRF-3 and the subsequent transcription of type I IFN genes [3, 14]. This block permits viral replication to proceed unabated in the early stages of infection, a critical window for establishing infection.

Yet, the virus-host interaction is further complicated by the generation of defective viral genomes (DVGs). These truncation products of genomic RNA arise spontaneously during viral replication and have historically been considered inert byproducts. However, the molecular pathogenesis of SeV cannot be understood without recognizing that DVGs are potent, immunostimulatory molecules. DVGs possessing complementary ends are exceptionally potent agonists of RIG-I, inducing a robust antiviral state in infected cells [9]. Specifically, a short, in vitro-generated DVG derived from SeV (DVG-324) induces high levels of IFN-β, TNF-α, and IL-6, and triggers the rapid mobilization of dendritic cells (DCs) in vivo [9]. This creates a fascinating paradox: while the full-length virus actively suppresses IFN responses via the C protein, the accumulation of DVGs simultaneously triggers a robust innate immune response within the same infected cell population.

Critically, this dynamic is spatially and temporally heterogeneous. Using RNA fluorescent in situ hybridization, researchers have demonstrated a striking dichotomy in infected cell populations. In cells enriched with full-length viral genomes, the genomes cluster in a perinuclear region and are associated with Rab11a and microtubules, enabling efficient packaging and budding. In contrast, in cells enriched with DVGs, the defective genomes are distributed diffusely throughout the cytoplasm and fail to engage this trafficking machinery [3]. Consequently, DVG-high cells become poor producers of viral particles but instead function as "sentinel cells," robustly activating antiviral immunity [3]. This heterogeneous response represents a novel immune evasion strategy at the population level: the virus ensures a steady supply of new virions from full-length genome-high cells, while DVG-high cells divert the host immune system into a state of hyperactivation, potentially leading to immunopathology or prolonged inflammation that may paradoxically aid viral persistence in the long term.

Modulation of Adaptive Cellular Immunity

Beyond innate signaling, SeV profoundly influences the adaptive immune response, particularly the function and fate of T cells. The virus’s capacity to establish persistent infections is intimately linked to its ability to modulate cytotoxic T lymphocyte (CTL) and T helper (Th) cell responses. Elegant studies in H-2Kb mutant mouse strains (B6.C-H-2bm1) have demonstrated that the generation of a robust CTL response is genetically restricted and is a critical determinant of survival. While C57BL/6 mice generate a strong, Kb-restricted SeV-specific CTL response, the bm1 mutant, which differs in just three amino acids in the Kb molecule, is a CTL non-responder [16]. These mice are significantly more susceptible to lethal pneumonia (LD50 of 14 TCID50) compared to wild-type B6 mice (LD50 of 152 TCID50), and T cell-deficient nu/nu mice are even more vulnerable (LD50 of 0.5 TCID50) [16]. This demonstrates that the MHC-restricted CTL response is a primary barrier against lethal disease.

SeV evades this CTL response through a combination of rapid replication and subtle immunoregulation. The virus induces a strong, but carefully tempered, CD8+ T cell response. Following intranasal inoculation, virus-specific CD8+ T cells persist in the diffuse nasal-associated lymphoid tissue (d-NALT) for at least 8 months, providing long-term protection [13]. However, these persisting T cells have a unique phenotype, producing low levels of cytokines, a characteristic that prevents excessive immunopathology in the delicate respiratory mucosa [13]. Furthermore, SeV appears to exploit the Th1/Th2 balance. The cooperation between Th and Tc cells is essential for clearing infection; administration of a mixture of SeV-specific Th and Tc clones, or a Tc clone plus recombinant IL-2, permanently protects lethally infected nu/nu mice, while either clone alone fails to provide complete protection [16]. This suggests that SeV’s evasion strategy may involve disrupting this cooperation, perhaps by limiting Th cell priming or by skewing the cytokine milieu away from a protective Th1 response. The resulting suboptimal CTL activity allows the virus to persist in the respiratory epithelium, a state that can be reactivated under immunosuppression.

Molecular Determinants of Host Range and Cross-Species Pathogenesis

The molecular pathogenesis of SeV is not confined to its natural murine host. The virus exhibits a remarkably broad host range in vitro, infecting a wide array of mammalian cells including those of human, monkey, and canine origin [6, 10]. This is mediated by the viral attachment protein (HN) which recognizes sialic acid residues that are ubiquitous on cell surfaces. While this broad tropism makes SeV an attractive vector for gene therapy and vaccine delivery, it also raises concerns regarding its potential for zoonotic spillover. Recent metagenomic surveys have identified SeV sequences in Malayan pangolins (Manis javanica), a protected species [1]. This discovery is significant for two reasons. First, it expands the known host range of SeV into an endangered mammal, suggesting a broader ecological niche than previously appreciated. Second, the presence of SeV in pangolins, which are known to harbor multiple viruses with zoonotic potential, underscores the need for ongoing surveillance to assess the risk of SeV adaptation to human hosts [1].

The oncolytic properties of SeV provide a unique window into its molecular pathogenesis in a therapeutic context. In canine patients with mast cell tumors, intratumoral injection of SeV led to complete responses in five of six animals, with long-term disease-free survival [4]. The virus kills cancer cells through multiple mechanisms, including direct lysis, induction of apoptosis, and stimulation of anti-tumor immune responses [7]. This is paradoxical: SeV can cause lethal respiratory disease in susceptible immunocompromised mice, yet it is safe and effective as an oncolytic agent in dogs. The explanation lies in the virus’s sensitivity to the host interferon system. In healthy cells with intact interferon signaling, SeV replication is rapidly curtailed [4, 12]. However, many cancer cells have defective interferon pathways, rendering them exquisitely sensitive to SeV-mediated oncolysis [7]. This differential susceptibility highlights that the molecular pathogenesis of SeV is not an inherent feature of the virus alone, but an emergent property of the interaction between viral immune evasion genes and the specific state of the host cell’s antiviral circuitry. The virus is a master of subversion, but its virulence is always conditional on the host’s immunological landscape.

Epidemiology and Cross-Species Transmission Dynamics of Sendai Virus

Sendai virus (SeV), the prototypical murine parainfluenza virus type 1 (murine PIV-1), occupies a unique and instructive niche within the paramyxovirus family. Its epidemiology is not defined by pandemic spread in human populations, but rather by its remarkable capacity for host-range flexibility, its utility as a model for understanding respiratory viral transmission, and its documented or suspected spillover into a diverse array of mammalian species. Understanding these dynamics is critical not only for evaluating the zoonotic or reverse-zoonotic potential of SeV itself but also for modeling the emergence pathways of related human pathogens, such as human parainfluenza virus type 1 (hPIV-1) and respiratory syncytial virus (RSV). The epidemiological landscape of SeV, as illuminated by the available literature, reveals a pathogen intricately balanced between a primary murine reservoir and a broad, yet often transient, capacity to infect non-rodent hosts, including humans, non-human primates, canines, and even phylogenetically distant species like pangolins.

Natural Reservoir Hosts and Primary Epidemiology

The foundational epidemiology of Sendai virus is rooted in its status as a natural pathogen of rodents, particularly laboratory mice. The virus is known to cause highly contagious respiratory infections, often epizootic, in mouse colonies, leading to significant morbidity and mortality, especially in naïve strains [16]. The classical model of SeV infection in mice provides a paradigm for understanding paramyxovirus pathogenesis. As detailed in seminal immunological studies, inbred mouse strains display marked differences in susceptibility, dictated largely by major histocompatibility complex (MHC) haplotype. For instance, C57BL/6 (H-2b) mice exhibit a relatively high lethal dose 50 (LD50) of 152 TCID50, whereas H-2Kb mutant B6.C-H-2bm1 (bm1) mice are far more susceptible (LD50 14 TCID50), and T-cell-deficient B6 nu/nu mice are exquisitely vulnerable (LD50 0.5 TCID50) [16]. This genetic determinism of disease outcome within a single reservoir species underscores the intricate co-evolutionary relationship between SeV and its murine host. The virus is maintained in wild and feral rodent populations, though comprehensive surveillance data from the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) for SeV in wild rodents is sparse compared to, for example, hantaviruses. Nevertheless, the laboratory mouse remains the best-characterized natural reservoir, where transmission occurs horizontally via the respiratory route, facilitated by the virus’s ability to replicate efficiently in the upper and lower respiratory tracts.

Evidence for Cross-Species Spillover and Host Range Expansion

A critical departure from a simple rodent-centric model is the growing body of evidence documenting SeV’s ability to cross species barriers. The most compelling evidence for this comes from a viral metagenomic survey of Malayan pangolins (Manis javanica), which identified SeV as one of the dominant viruses present in these endangered mammals [1]. This finding is of profound epidemiological significance. Pangolins are ancient mammals with a unique immune system, and their role as a potential mixing vessel for paramyxoviruses and coronaviruses has been a subject of intense scrutiny since the COVID-19 pandemic. The detection of SeV in pangolins, which are evolutionarily distant from rodents, indicates that this virus possesses a receptor-binding and entry machinery capable of utilizing surface molecules on cells from a wide range of mammalian orders. This is not a laboratory artifact but a natural occurrence, suggesting that SeV (or a very close variant) can spill over into novel hosts in the wild. The Centers for Disease Control and Prevention (CDC) and WOAH would classify this as a significant finding for emerging infectious disease surveillance, as it demonstrates an unanticipated host range that could facilitate further adaptation.

Further evidence of cross-species transmissibility is provided by experimental and clinical studies in non-human primates and humans. SeV has been extensively tested as a Jennerian vaccine vector for human parainfluenza virus type 1 (hPIV-1) and as a backbone for RSV vaccines [2, 12]. In these studies, replication-competent SeV was administered intranasally to African green monkeys (AGMs) and, in a first-in-human trial, to healthy human adults [2, 12]. The key epidemiological insight from these experiments is that SeV can infect and replicate in both AGMs and humans, but its transmission is highly restricted. In AGMs, the vaccine virus was cleared from both the upper and lower respiratory tracts by day 10 post-inoculation, and no onward transmission to sentinel animals was reported [12]. In the human trial, viral genome detection in nasal washes was described as "transient," with no evidence of prolonged shedding or transmission [2]. This pattern, infection without sustained transmission, is characteristic of a "dead-end" spillover event. The virus can establish a primary infection and elicit an immune response, but it lacks the necessary adaptations for efficient person-to-person spread. The pre-existing immunity in the adult human population, particularly from prior exposure to hPIV-1, likely acts as a potent immunological barrier [2], highlighting the role of cross-reactive immunity in limiting the spread of a rodent virus in humans.

Mechanistic Basis for Transmission Barriers and Cross-Species Infection

The ability of SeV to infect a wide range of cell types in vitro and in vivo yet fail to transmit efficiently in humans is a classic conundrum in viral emergence. The molecular basis for this is multifaceted. The virus’s entry is mediated by the hemagglutinin-neuraminidase (HN) protein, which binds to sialic acid receptors. Sialic acids are ubiquitous on mammalian cells, providing a low barrier for initial infection. However, post-entry replication, host interferon antagonism (via the C and V proteins), and evasion of intrinsic immunity are likely highly species-specific. Studies using SeV-derived vectors for gene therapy and iPSC reprogramming have demonstrated that the virus can efficiently deliver genetic payloads to a vast array of human cells, including hematopoietic stem cells, airway epithelial cells, and primary fibroblasts [5, 6, 8, 14]. This demonstrates a very low barrier to cellular entry and gene expression. The transmission bottleneck, therefore, is not at the level of cellular infection but at the level of host defense, transmission efficiency, and mucosal immunity.

Another layer of complexity is added by the generation of defective viral genomes (DVGs) during replication. DVGs are powerful immunostimulatory molecules that trigger RIG-I signaling and induce a potent antiviral state [3, 9]. The ecological and epidemiological consequence of DVGs is that they influence both within-host and between-host dynamics. Cells high in DVGs become poor producers of infectious viral particles but potent activators of the immune system, effectively acting as "firewalls" that limit viral spread within the host [3]. This phenomenon may be particularly pronounced in a mismatched host like a human, where suboptimal replication fidelity or host factor incompatibility leads to higher DVG accumulation, thereby throttling transmission. In contrast, in the natural murine host, the virus-host interaction is more balanced, allowing for efficient production of full-length, transmissible particles.

Implications for Emerging Infectious Disease Surveillance and Veterinary Medicine

The epidemiological footprint of SeV extends beyond the laboratory and into the field of veterinary oncology. A pilot study investigating oncolytic SeV therapy for canine mast cell tumors demonstrated that the virus could be safely administered to dogs, with documented oncolytic efficacy [4]. This not only confirms that dogs are susceptible to SeV infection (albeit via intratumoral injection) but also raises the possibility of natural exposure. If SeV can infect dogs, it may circulate subclinically in canine populations, especially in environments with high rodent densities. This creates a potential bridge for transmission between rodents, companion animals, and humans, a scenario that WOAH would flag for surveillance in animal health networks.

From a One Health perspective, the finding of SeV in pangolins is a sentinel event [1]. It suggests that other, as-yet-undetected paramyxoviruses may be circulating in wildlife with an even broader host range. The epidemiological lesson is clear: SeV is not merely a mouse virus. It is a pathogen that has demonstrated the capacity to jump into at least three distinct mammalian orders (Rodentia, Pholidota, and Primates, including humans). While it has not yet established itself as a sustained human pathogen, the partial replication seen in human phase I trials [2] and the complete replication in AGMs [12] indicate that the species barrier is not absolute. Continued surveillance of respiratory illnesses in exotic animal markets, wildlife rehabilitation centers, and veterinary clinics is warranted, using metagenomic approaches capable of detecting paramyxoviruses with broad receptor tropism.

In conclusion, the epidemiology of Sendai virus is characterized by a stable, highly adapted circulation within murine rodents, punctuated by frequent but typically abortive spillover events into a range of other mammals. The virus’s ability to infect cells from diverse species is well-established, but its transmission fails in non-rodent hosts due to a combination of pre-existing cross-reactive immunity, rapid clearance, and the inherent biological stability of the murine-adapted genome. The documented presence of SeV in an endangered species like the Malayan pangolin serves as a powerful reminder that the host range of RNA viruses is often far larger than currently appreciated. This positions SeV as an important model for both understanding the fundamental immunology of cross-species transmission and for calibrating surveillance efforts for emerging paramyxoviruses with pandemic potential.

Genomic Structure and Reverse Genetics of Sendai Virus

The genomic architecture of Sendai virus (SeV) exemplifies the hallmark organization of the Paramyxoviridae family, yet harbors unique structural and functional attributes that have rendered it an indispensable platform for reverse genetics, vaccine development, and gene therapy. As a negative-sense, single-stranded RNA virus belonging to the genus Respirovirus, SeV possesses a non-segmented genome of approximately 15,384 nucleotides, a size that is remarkably conserved among murine parainfluenza viruses. The genome is encapsidated by the nucleoprotein (NP) to form a helical ribonucleocapsid (RNP) complex, which serves as the template for both transcription and replication. This RNP is the minimal infectious unit, as naked viral RNA is neither infectious nor translatable in the host cytoplasm, a critical constraint that underpins the design of reverse genetics systems. The genomic organization follows the canonical paramyxovirus gene order: 3′-NP-P-M-F-HN-L-5′, with each gene flanked by conserved transcriptional start and stop signals that govern a gradient of gene expression, wherein promoter-proximal genes (e.g., NP) are transcribed at higher levels than distal genes (e.g., L). This polarity is a direct consequence of the viral RNA-dependent RNA polymerase (RdRp) complex, composed of the large protein (L) and the phosphoprotein (P), which initiates transcription at the 3′ leader region and sequentially reinitiates at each gene junction, with a defined probability of fall-off at each intergenic boundary.

The leader and trailer regions at the 3′ and 5′ ends of the genome are cis-acting elements of paramount importance. The 3′ leader (approximately 55 nucleotides) contains the promoter for both transcription and replication, while the 5′ trailer (approximately 57 nucleotides) is essential for encapsidation and genome packaging. These regions are highly complementary, forming panhandle structures that are recognized by the polymerase complex. The intergenic regions, though short (typically 1–3 nucleotides), are not merely passive spacers; they contribute to the efficiency of transcriptional reinitiation and are critical for the maintenance of the gene order. The P gene is particularly notable for its complex expression strategy: it encodes not only the P protein but also the C proteins (C′, C, Y1, Y2) via a ribosomal leaky scanning mechanism, and the V protein via a cotranscriptional RNA editing event that inserts a single G residue at a conserved editing site. This editing frequency is tightly regulated and results in a population of mRNAs that encode either the P protein (unedited) or the V protein (edited). The V protein, a zinc-binding protein containing a cysteine-rich domain, is a potent antagonist of the host interferon response, targeting the STAT1 and STAT2 signaling pathways. The C proteins, though smaller, also contribute to immune evasion and modulation of viral RNA synthesis. This genetic economy, wherein a single gene yields multiple functionally distinct polypeptides, is a hallmark of paramyxoviruses and is essential for SeV’s ability to establish productive infections in murine hosts while maintaining a narrow host range.

The fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins are embedded in the viral envelope and mediate host cell entry. The HN protein binds to sialic acid-containing receptors on the host cell surface, while the F protein, after proteolytic cleavage by host proteases, mediates membrane fusion. The matrix (M) protein orchestrates viral assembly and budding, interacting with both the RNP and the cytoplasmic tails of the glycoproteins. The L protein, the largest of the viral proteins (approximately 2,228 amino acids), harbors the RdRp activity, as well as capping, methylation, and polyadenylation functions. The P protein acts as a cofactor, stabilizing the L protein and facilitating its interaction with the NP-encapsidated genome. The NP protein is composed of an N-terminal core domain that binds RNA and a C-terminal tail that interacts with the P protein during replication. The precise stoichiometry of these proteins within the RNP is critical; each NP monomer binds approximately six nucleotides of RNA, a rule that must be strictly adhered to for efficient replication.

The advent of reverse genetics for SeV, first achieved in the late 1990s, revolutionized the study of this virus. The system relies on the intracellular reconstitution of the RNP from plasmid-encoded components. Typically, a full-length cDNA copy of the SeV genome is cloned under the control of a T7 RNA polymerase promoter, flanked by a hammerhead ribozyme at the 5′ end and a hepatitis delta virus ribozyme at the 3′ end to generate precise genomic termini. This plasmid is co-transfected into cells (e.g., BSR T7/5 cells stably expressing T7 polymerase) with support plasmids encoding the NP, P, and L proteins. The intracellularly assembled RNP then initiates transcription and replication, ultimately producing infectious recombinant virus. This technology has enabled the systematic dissection of every cis-acting element and protein-coding region. For instance, the generation of recombinant SeV expressing enhanced green fluorescent protein (eGFP) fused to the L protein (rSeVLeGFP) allowed real-time visualization of vRNP trafficking along microtubules, revealing a previously unrecognized role for Rab11a-positive recycling endosomes in vRNP translocation to assembly sites [15]. Such studies have demonstrated that vRNPs move in a directional, saltatory manner, and that disruption of microtubules with nocodazole severely impairs progeny virion production without affecting viral protein synthesis [15]. This underscores the intimate coupling between genomic trafficking and productive infection.

Reverse genetics has also been instrumental in engineering SeV as a vaccine vector. The insertion of foreign genes, such as the respiratory syncytial virus (RSV) fusion protein (F) gene, into the SeV genome between the P and M genes has yielded the vaccine candidate SeVRSV [2, 12]. This recombinant virus replicates to high titers, expresses the RSV F protein on the cell surface, and induces robust humoral and cellular immune responses. In African green monkeys, a single intranasal and intratracheal administration of SeVRSV conferred complete protection against RSV challenge in the lower respiratory tract, with no detectable vaccine-related adverse events [12]. Similarly, the insertion of the influenza A virus hemagglutinin (HA) gene into the SeV genome (GP42-H1) generated a mucosal vaccine that induced HA-specific IgG and IgA antibodies in serum, bronchoalveolar lavage, and fecal extracts, and protected mice from lethal influenza challenge without causing weight loss or disease symptoms [17]. These successes highlight the flexibility of the SeV genome to accommodate additional transcriptional units, typically up to 3–4 kb, without compromising viral fitness.

The development of defective and persistent SeV vectors (SeVdp) represents a further refinement of reverse genetics for gene therapy and cellular reprogramming. By deleting the F gene and introducing temperature-sensitive mutations, researchers have created vectors that are replication-defective yet capable of stable, long-term transgene expression in the cytoplasm [14]. These SeVdp vectors can carry up to four exogenous genes (e.g., Oct4, Sox2, Klf4, and c-Myc) and efficiently reprogram human somatic cells into induced pluripotent stem cells (iPSCs) without any risk of genomic integration [5, 8, 11]. The absence of a DNA phase in the SeV life cycle eliminates the possibility of insertional mutagenesis, a critical safety advantage over retroviral and lentiviral vectors. Furthermore, the SeVdp vector can be rapidly eliminated from target cells by RNA interference, allowing precise temporal control over transgene expression [14]. This has been exploited for CRISPR/Cas9 delivery, where SeV vectors achieved on-target mutagenesis rates of 75–98% in cell lines and 88% in primary human monocytes at the ccr5 locus, without detectable off-target integration [6]. The cytoplasmic replication of SeV also avoids the epigenetic silencing often encountered with nuclear-delivered transgenes, ensuring robust and sustained expression.

The generation of defective viral genomes (DVGs) during SeV replication is an intrinsic feature of the viral RdRp, which frequently produces truncated or rearranged genomes due to polymerase slippage or premature termination. These DVGs, particularly those with complementary ends, are potent agonists of the RIG-I-like receptor pathway, inducing high levels of type I interferons and pro-inflammatory cytokines [9]. Reverse genetics has been used to engineer defined DVGs, such as DVG-324, a 324-nucleotide RNA derived from the SeV genome that retains strong immunostimulatory activity. When used as an adjuvant, DVG-324 enhances antibody responses to co-administered antigens and mobilizes dendritic cells in vivo, with a cytokine profile distinct from that of poly(I:C) [9]. This opens avenues for the rational design of next-generation vaccine adjuvants. Moreover, the heterogeneity in DVG content among infected cells has been shown to dictate functional outcomes: cells enriched in full-length genomes are the primary producers of viral particles, while DVG-high cells poorly engage the packaging machinery but strongly stimulate antiviral immunity [3]. This functional dichotomy, revealed through RNA fluorescence in situ hybridization and reverse genetics, underscores the complex interplay between viral genome structure and host cell biology.

The reverse genetics platform has also enabled the pseudotyping of other viral vectors with SeV envelope proteins, expanding the tropism of gene delivery vehicles. For example, a simian immunodeficiency virus (SIV) pseudotyped with SeV F and HN proteins efficiently transduces human airway epithelial cells from the apical surface, a major barrier for cystic fibrosis gene therapy [18]. This vector achieved durable transgene expression for up to 15 months in murine nasal epithelium without preconditioning, and restored functional CFTR chloride channels in human air-liquid interface cultures [18]. The ability to combine the high infectivity of SeV glycoproteins with the stable integration capacity of lentiviruses represents a powerful hybrid approach.

In summary, the genomic structure of Sendai virus, with its non-segmented negative-sense RNA, conserved gene order, and complex transcriptional editing, provides a versatile scaffold for reverse genetics. The ability to rescue recombinant viruses, insert foreign genes, engineer temperature-sensitive mutations, and generate defined DVGs has propelled SeV from a model paramyxovirus to a clinically relevant vector for vaccination, oncolytic virotherapy, and regenerative medicine. The cytoplasmic replication cycle, absence of DNA intermediates, and wide host range further enhance its utility, while the detailed understanding of cis-acting elements and protein functions continues to inform the design of safer and more efficacious derivatives. As reverse genetics technologies advance, the potential for SeV-based platforms to address unmet medical needs, from respiratory syncytial virus and influenza to cancer and genetic disorders, remains vast and largely untapped.

Diagnostics and Viral Metagenomic Detection of Sendai Virus

The detection and characterization of Sendai virus (SeV), a prototypical member of the Paramyxoviridae family within the genus Respirovirus, necessitates a multifaceted diagnostic approach that integrates classical virological techniques with cutting-edge molecular and metagenomic platforms. Given SeV’s dual relevance as a natural pathogen of laboratory rodents and a burgeoning platform for vaccine development, gene therapy, and oncolytic virotherapy, the diagnostic landscape must be both sensitive and specific, capable of distinguishing between wild-type infections, recombinant vaccine strains, and defective interfering particles. The advent of viral metagenomics has fundamentally expanded our capacity to survey SeV across diverse ecological niches, revealing its presence in unexpected hosts and underscoring its potential for cross-species transmission.

Classical Diagnostic Modalities: Serology, Virus Isolation, and Immunoassays

Historically, the diagnosis of Sendai virus infection in laboratory rodent colonies has relied upon serological surveillance and virus isolation. Enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence assays (IFAs) targeting antibodies against the viral hemagglutinin-neuraminidase (HN) and fusion (F) proteins remain cornerstones of colony health monitoring. These assays are highly effective for detecting past or ongoing infections in mice, rats, and hamsters, where SeV is a common enzootic pathogen. However, serological cross-reactivity with other paramyxoviruses, particularly human parainfluenza virus type 1 (hPIV-1), can complicate interpretation, a factor critically important when SeV is used as a Jennerian vaccine for hPIV-1 [2, 12]. Indeed, pre-existing immunity to hPIV-1 in human adults has been shown to transiently suppress detectable antibody responses to SeV-based vaccines, necessitating the use of more sensitive molecular detection methods in clinical trials [2].

Virus isolation in embryonated chicken eggs or permissive cell lines (e.g., LLC-MK2, Vero, or CV-1 cells) remains a gold standard for obtaining live virus for characterization. The cytopathic effect (CPE) of SeV, characterized by syncytia formation due to the F protein’s fusogenic activity, is a hallmark of productive infection. However, isolation is time-consuming and may fail if the virus is present in low titers or is inactivated. Furthermore, the presence of defective viral genomes (DVGs), which are abundant during SeV replication, can confound isolation efforts. DVGs, which arise from erroneous RNA-dependent RNA polymerase (RdRp) activity, are preferentially replicated in certain cellular subpopulations and can dominate the viral quasispecies, leading to attenuated CPE and altered growth kinetics [3]. This functional heterogeneity, where DVG-high cells poorly produce viral particles while DVG-low cells are the primary producers, underscores the need for molecular diagnostics that can discriminate between full-length and defective genomes [3].

Molecular Detection: RT-PCR, Real-Time qPCR, and Strain Differentiation

Reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variant (RT-qPCR) have become the workhorses for SeV detection due to their speed, sensitivity, and specificity. Primers are typically designed to target highly conserved regions of the nucleoprotein (N) or matrix (M) genes, enabling detection across different SeV strains. For vaccine and vector applications, RT-qPCR is indispensable for monitoring viral genome clearance. In the clinical trial of the SeVRSV vaccine (a recombinant SeV expressing the respiratory syncytial virus F protein), nasal wash samples were analyzed by RT-qPCR to track vaccine shedding. The study demonstrated that genome detection was transient in seropositive adults, with viral RNA becoming undetectable within two weeks post-vaccination, correlating with pre-existing mucosal immunity [2]. This approach is critical for safety assessments, ensuring that replication-competent vaccine vectors do not persist or revert to virulence.

A more nuanced challenge is the detection and quantification of DVGs. Standard RT-qPCR using primers spanning the entire genome may fail to distinguish between full-length and defective genomes. To address this, researchers have developed DVG-specific RT-PCR assays that target the unique junction sequences formed during copy-back or deletion events. For instance, the highly immunostimulatory DVG-324, a short SeV-derived RNA, can be specifically amplified using primers flanking its deletion breakpoint [9]. This capability is vital for understanding the immunobiology of SeV infection, as DVGs are potent agonists of RIG-I-like receptors (RLRs) and drive the antiviral interferon response [3, 9]. In the context of oncolytic virotherapy, monitoring DVG accumulation is essential, as DVGs can enhance antitumor immunity by stimulating dendritic cell maturation and T-cell activation, but may also limit viral replication and oncolytic efficacy [4, 7].

Viral Metagenomics: Unbiased Discovery and Ecological Surveillance

The application of viral metagenomics has revolutionized our understanding of SeV’s host range and evolutionary dynamics. Unlike targeted PCR, metagenomic sequencing (e.g., using Illumina or Nanopore platforms) allows for the unbiased detection of all viral nucleic acids in a sample, enabling the discovery of novel SeV variants and their association with previously unsuspected hosts. A landmark study employing viral metagenomics on Malayan pangolins (Manis javanica) identified SeV as one of the dominant viruses in the virome, alongside coronavirus [1]. From 62,508 de novo assembled contigs, 68 showed high sequence similarity to known viruses, with SeV contigs being among the most abundant. This finding is of profound epidemiological significance, as pangolins are endangered mammals that may serve as reservoirs for viruses capable of crossing into other mammals, including humans. The detection of SeV in pangolins expands the known host range beyond rodents and suggests that paramyxovirus surveillance in wildlife must be prioritized to preempt zoonotic spillover events [1].

Metagenomics also provides a powerful tool for characterizing the genetic diversity of SeV in laboratory settings. The technique can simultaneously detect wild-type SeV, recombinant vaccine strains (e.g., SeVRSV or GP42-H1 expressing influenza HA), and defective interfering particles [2, 17]. By sequencing total RNA from infected cell cultures or animal tissues, researchers can assemble the full-length viral genome and identify mutations associated with attenuation, host adaptation, or immune evasion. For example, the development of the defective and persistent SeV vector (SeVdp) for iPSC reprogramming relied on precise genetic modifications to render the virus non-cytopathic and replication-defective [10, 14]. Metagenomic sequencing confirmed the absence of wild-type revertants and validated the stability of the engineered genome, a critical safety requirement for clinical-grade vector production [11].

Advanced Detection in Gene Therapy and Vaccine Contexts

The use of SeV as a gene delivery vector, for CRISPR/Cas9 editing, iPSC reprogramming, or oncolysis, imposes stringent requirements on diagnostic methods. Since SeV replicates exclusively in the cytoplasm with no DNA intermediate, there is no risk of genomic integration, a key advantage over lentiviral or retroviral vectors [5, 6]. However, this also means that detection must rely entirely on RNA-based methods. For iPSC generation, the persistence of SeV-derived transgenes (e.g., Oct4, Sox2, Klf4, c-Myc) must be monitored to ensure that reprogrammed cells are transgene-free before clinical use. RT-qPCR targeting the SeV backbone or the transgene sequences is routinely employed, and viral RNA is typically lost over successive cell divisions [5, 8]. In cases where residual SeV RNA persists, antibody-mediated negative selection using the cell surface HN protein can eliminate infected cells, a strategy validated in human iPSC lines [5].

For oncolytic SeV therapy, diagnostics must also assess viral distribution and clearance in the tumor microenvironment and systemic circulation. In a pilot study of canine mast cell tumors, intratumoral injection of SeV was monitored by RT-PCR of tumor biopsies, confirming viral replication within the lesion [4]. The detection of viral RNA correlated with therapeutic response, as five of six dogs achieved complete remission. Metagenomic analysis of these tumors could further reveal whether DVGs or other viral variants emerge during treatment, potentially influencing immunogenicity and efficacy [7].

Regulatory and Public Health Considerations

From a regulatory perspective, the detection of SeV in biological products, such as vaccines produced in embryonated eggs or cell lines, is mandated by agencies like the World Organisation for Animal Health (WOAH) and the U.S. Department of Agriculture (USDA). SeV is a known adventitious agent in rodent-derived materials, and its presence can compromise product safety. The U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) also recognize the potential for paramyxoviruses to emerge from animal reservoirs, as evidenced by the pangolin virome study [1]. Therefore, robust metagenomic surveillance programs, akin to those used for influenza and coronaviruses, are recommended for monitoring SeV in wildlife and livestock.

In conclusion, the diagnostic toolkit for Sendai virus has evolved from classical serology and virus isolation to a sophisticated array of molecular and metagenomic methods. RT-qPCR remains the gold standard for quantitative detection in clinical and research settings, while viral metagenomics offers unparalleled power for discovery and ecological surveillance. The ability to discriminate between full-length genomes, DVGs, and recombinant vectors is essential for understanding SeV biology, ensuring the safety of SeV-based therapeutics, and monitoring its potential for cross-species transmission. As SeV continues to be deployed as a vaccine vector, gene therapy tool, and oncolytic agent, the integration of these diagnostic modalities will be paramount for both basic research and translational applications.

Sendai Virus-Based Vaccine Vectors for Human Parainfluenza and Respiratory Syncytial Virus

The development of safe and efficacious vaccines against human parainfluenza viruses (hPIVs) and respiratory syncytial virus (RSV) has been a decades-long pursuit, fraught with immunological and virological challenges. These pathogens collectively represent the leading causes of acute lower respiratory tract infections (ALRI) in infants, young children, the immunocompromised, and the elderly, imposing a global disease burden that the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recognize as a critical unmet medical need. Traditional vaccine approaches, including formalin-inactivated preparations, have historically failed or, in the case of RSV, led to enhanced respiratory disease upon natural infection. Within this landscape, Sendai virus (SeV), the murine counterpart of human parainfluenza virus type 1 (hPIV-1), has emerged as a uniquely powerful and versatile platform for mucosal vaccine vector design. Its natural biology, cytoplasmic replication cycle, and proven capacity to elicit durable, protective immunity at the respiratory mucosa make it an ideal chassis for engineering multivalent vaccines targeting both hPIV-1 and RSV.

The Jennerian Foundation: Sendai Virus as a Vaccine for Human Parainfluenza Virus Type 1

The conceptual basis for using SeV as a vaccine vector for human respiratory viruses is rooted in a classic Jennerian principle: a closely related virus from a different host species can safely induce cross-protective immunity against a human pathogen. SeV is the murine parainfluenza virus type 1, sharing extensive antigenic and structural homology with its human counterpart, hPIV-1. Importantly, SeV is non-pathogenic in humans, a property that is fundamental to its safety profile. This natural relationship positions unmanipulated, non-recombinant SeV as a live, attenuated vaccine candidate for hPIV-1 itself [2, 12].

The biological plausibility of this approach is robustly demonstrated in non-human primate models. African green monkeys (AGMs), which are permissive to both SeV and hPIV-1 infection, are a gold-standard preclinical model for evaluating respiratory virus vaccines. Intranasal and intratracheal administration of wild-type SeV to AGMs confers sterilizing immunity against subsequent challenge with hPIV-1, providing complete protection from infection in the upper and lower respiratory tracts [2, 12]. This protection is mechanistically linked to the induction of potent, multi-faceted immune responses at the mucosa. Intranasal inoculation with SeV elicits virus-specific antibody-forming cells (AFCs) and CD8+ T cells that persist within the diffuse nasal-associated lymphoid tissue (d-NALT) for at least eight months in murine models [13]. These AFCs produce a diverse panel of immunoglobulin isotypes, including IgG1, IgG2a, IgG2b, and critically, secretory IgA, which is instrumental in neutralizing pathogens at the point of entry [13]. The virus-specific CD8+ T cells are cytolytic and exhibit functional profiles that mirror long-lived effector memory cells found in the gut, ensuring rapid recall responses upon re-exposure [13]. The reliance on robust T cell immunity is further underscored by classic immunological studies in mice, which demonstrate that cooperation between H-2Kb-restricted cytotoxic T lymphocytes (Tc) and I-Ab-restricted helper T lymphocytes (Th) is absolutely essential for survival against lethal Sendai virus challenge. In these models, neither Tc nor Th clones alone could confer permanent survival in T cell-deficient nude mice; only a combination of both, or a Tc clone supplemented with recombinant IL-2, achieved complete protection [16]. This highlights the critical, non-redundant role of coordinated cellular immunity, a principle that directly informs the design of SeV-based vectors.

The SeVRSV Platform: Engineering a Bivalent Vaccine Against RSV

Building upon the proven efficacy of SeV against hPIV-1, the platform was rationally extended to target RSV, arguably the most consequential respiratory pathogen of early childhood for which no licensed vaccine exists. The recombinant vector, designated SeVRSV, was constructed using reverse genetics to insert the full-length gene encoding the RSV fusion (F) glycoprotein into the SeV genome [2, 12]. The RSV F protein is a conserved, essential target of neutralizing antibodies and is the antigenic component of choice for nearly all RSV vaccine strategies. By embedding this transgene into the replication-competent SeV backbone, the vector achieves dual functionality: it simultaneously immunizes against both hPIV-1 (via the SeV backbone itself) and RSV (via expression of the heterologous F protein).

The preclinical evaluation of SeVRSV in the AGM model yielded results that are genuinely striking and have paved the way for clinical translation. AGMs vaccinated with a single intranasal and intratracheal dose of SeVRSV, without any booster immunization, developed robust antibody responses. Serum and nasal wash antibodies specific to both SeV and RSV F were detectable as early as ten days post-vaccination [12]. The critical test of efficacy came one month later, when all animals were challenged with a high dose of RSV-A2. The results demonstrated a clear dichotomy in protection: SeVRSV-vaccinated animals exhibited significantly reduced RSV titers in the upper respiratory tract (URT) compared to controls, but, most importantly, they demonstrated complete protection against RSV in the lower respiratory tract (LRT) [12]. No viral replication was detectable in the lungs of vaccinated AGMs. This complete LRT protection is the sine qua non for a pediatric RSV vaccine, as the goal is to prevent the bronchiolitis and pneumonia that drive hospitalization. Furthermore, there were no clinically relevant adverse events associated with vaccination, and the vaccine virus was cleared from both the URT and LRT by day 10, demonstrating a self-limiting infection that does not persist [12].

Clinical Translation and the Challenge of Preexisting Immunity

The promising preclinical data from AGMs provided the necessary impetus for the first-in-human clinical trial of SeVRSV, a landmark study that represents the first report of a SeV-based vaccine administered to healthy adults [2]. This phase 1 trial enrolled 17 healthy adults who received a single intranasal dose of SeVRSV, with four additional subjects receiving a placebo. The primary objectives were safety, tolerability, and assessment of viral genome shedding and immunogenicity. The results were highly informative and instructive for the future developmental path of this vaccine platform.

From a safety standpoint, the vaccine was extremely well-tolerated. All reported adverse events were mild to moderate, equally distributed between vaccine and placebo groups, and no severe adverse events (SAEs) or new onset chronic medical conditions (NOCMCs) occurred [2]. This safety profile in a naïve human population is consistent with the decades of safe use of SeV in laboratory settings and its lack of pathogenicity in humans.

However, as predicted by the investigators, the immunogenicity data in this adult cohort were tempered by a powerful immunological obstacle: preexisting immunity. All adult subjects had naturally acquired antibodies against hPIV-1 and RSV from prior childhood infections. Consequently, the vaccine virus genome was only transiently detected in nasal washes, and the antibody responses to the vaccine were minimal. There was a negligible increase in antibodies to RSV F, and only modest responses to the SeV backbone [2]. This is a classic challenge for live-vectored vaccines in seropositive populations; pre-existing neutralizing antibodies can rapidly clear the vaccine vector before it has the opportunity to replicate sufficiently and drive a robust recall response. This finding does not diminish the potential of the vaccine but rather refines its target population. The authors explicitly concluded that these results encourage further studies of SeVRSV with progression toward clinical trials in seronegative children [2], the very population that stands to benefit most from a vaccine against these primary pathogens.

The Power of Mucosal Immunity and the Role of Defective Viral Genomes

A distinguishing and advantageous feature of the SeV vaccine platform is its natural tropism for and administration via the respiratory mucosa. Intranasal delivery is the route of inoculation, directly targeting the airway epithelium where hPIV and RSV initiate infection. This strategy is fundamentally different from parenteral injection, which is less effective at inducing local mucosal immune responses. The SeV vector, as a replication-competent virus, engages the full arsenal of the mucosal immune system. It establishes a transient, localized infection in the nasal epithelium, which triggers the activation of Pattern Recognition Receptors (PRRs), most notably RIG-I, in the cytoplasm [9]. This leads to the production of type I interferons and pro-inflammatory cytokines, creating a potent immunostimulatory environment that is ideally suited for driving adaptive immunity.

Remarkably, this immunostimulatory capacity is not solely dependent on the replication-competent full-length virus. Defective viral genomes (DVGs), which are naturally generated during SeV replication in a subpopulation of infected cells, have been identified as exceptionally potent immunostimulatory molecules. DVGs are truncated viral genomes that arise from errors in the viral RNA-dependent RNA polymerase. Genoyer and López demonstrated that cells enriched in DVGs show a diffuse cytoplasmic distribution of these genomes, fail to effectively engage the viral budding machinery, and thus do not produce large quantities of viral particles [3]. Instead, these DVG-high cells become potent factories of innate immune signaling. DVGs bearing complementary ends are particularly strong agonists of the RIG-I pathway, inducing dendritic cell (DC) maturation and the expression of high levels of antiviral and pro-inflammatory cytokines [9]. This phenomenon has been harnessed to create a defined, short SeV-derived DVG RNA, known as DVG-324, which retains full immunostimulatory activity. When used as an adjuvant, DVG-324 can significantly enhance antibody production to a co-administered vaccine antigen in mice, and the cytokine profile it induces is distinct from that of poly I:C, suggesting a unique mechanism of action [9]. This intrinsic adjuvant activity, embedded within the very replication cycle of the vector, provides a built-in mechanism to boost the adaptive immune response to the co-expressed heterologous antigen, such as the RSV F protein.

A Versatile Platform for Other Respiratory Pathogens and Future Directions

The modular nature of the SeV reverse genetics system allows for the insertion of foreign genes from other respiratory pathogens, making it a pan-respiratory virus vaccine platform. This has been successfully demonstrated by the construction of GP42-H1, a recombinant attenuated Sendai virus vector that expresses the hemagglutinin (HA) gene from influenza A virus [17]. Intranasal immunization of mice with a remarkably low dose (1000 plaque-forming units) of GP42-H1 induced robust HA-specific IgG and IgA antibodies in the blood, bronchoalveolar lavage fluid, and fecal extracts [17]. Most impressively, immunized mice were fully protected against a lethal challenge with 5 LD50 (1250 pfu) of influenza virus, showing no weight loss or morbidity [17]. This level of protection, achieved without causing any disease symptoms or body weight loss from the vaccine itself, underscores the safety and efficacy of the platform.

The unique biological properties of SeV provide profound safety advantages for a pediatric vaccine vector. As a negative-sense RNA virus, SeV replicates entirely in the cytoplasm and has no DNA phase. This eliminates any risk of integration of the vector genome or transgene into the host chromosomal DNA, a critical safety consideration for any vaccine intended for widespread use in infants and children [5, 6, 10, 14]. Furthermore, the ability to engineer defective and persistent (SeVdp) vectors, which are non-cytopathic and can stably express transgenes without causing cell lysis, offers another layer of control and flexibility for future vaccine designs [14].

In summary, the Sendai virus-based vaccine platform represents a paradigm shift in the approach to vaccinating against human parainfluenza virus type 1 and respiratory syncytial virus. Its Jennerian foundation provides a natural vaccine for hPIV-1, while its reverse genetics capacity allows for the stable expression of protective antigens from RSV and other respiratory viruses. The compelling preclinical protection data in non-human primates, the excellent safety profile in adult humans, and the unique route of mucosal immunization that leverages the potent immunostimulatory power of both the full-length virus and its defective genomes, all point to a vector system that is ideally suited for the seronegative infant population. The challenge of preexisting immunity in adults does not diminish its promise; instead, it highlights the precise clinical niche this vector is designed to fill. As clinical development progresses to the target pediatric population, the SeVRSV vaccine candidate stands as a leading contender to address one of the most persistent and tragic gaps in global childhood health.

Zoonotic Potential and Virome Surveillance of Sendai Virus in Wildlife

The question of whether Sendai virus (SeV) possesses a genuine zoonotic potential, that is, the capacity for direct transmission from its canonical murine reservoir to humans, remains one of the most nuanced and critically debated topics in paramyxovirology. While SeV is historically classified as a murine parainfluenza virus type 1 (murine PIV-1) and is considered enzootic in rodent populations, the expanding frontier of wildlife virome surveillance has fundamentally challenged the assumption of strict host restriction. The detection of SeV in Malayan pangolins (Manis javanica), as reported by Liu et al. in 2019, represents a paradigm-shifting event that compels a rigorous re-evaluation of the virus’s ecological plasticity and its potential to bridge species barriers [1]. This section provides an exhaustive analysis of the biological mechanisms underpinning SeV’s host range, the epidemiological implications of its detection in novel wildlife hosts, and the strategic importance of ongoing virome surveillance in the context of global pandemic preparedness.

The Biological Basis of Host Range and Cross-Species Transmission

To understand the zoonotic potential of SeV, one must first dissect the molecular determinants of its host range. SeV, like all paramyxoviruses, initiates infection via the interaction of its hemagglutinin-neuraminidase (HN) glycoprotein with sialic acid-containing receptors on the host cell surface. The specificity of this interaction is a primary barrier to cross-species transmission. In mice, the virus efficiently utilizes α2,3-linked sialic acids, which are abundant on murine respiratory epithelium. However, the human respiratory tract is dominated by α2,6-linked sialic acids, a difference that historically provided a mechanistic explanation for the apparent lack of sustained human infection by wild-type SeV. This receptor tropism is the cornerstone of the “Jennerian” vaccine approach, wherein unmanipulated SeV is used as a live, attenuated vaccine against human parainfluenza virus type 1 (hPIV-1) in non-human primates and is being evaluated in clinical trials for safety in humans [2, 12]. The fact that SeV can replicate in the upper respiratory tract of African green monkeys (AGM) and, transiently, in seronegative human adults, demonstrates that the host range barrier is not absolute [2, 12]. The virus can infect human cells, but replication is typically curtailed by pre-existing immunity to the antigenically related hPIV-1 and by the innate immune response. This is a critical point: the barrier is not a complete inability to enter human cells, but rather a combination of suboptimal receptor engagement and robust immune surveillance.

The detection of SeV in pangolins introduces a new layer of complexity. Pangolins are phylogenetically distant from rodents, belonging to the order Pholidota. The finding of SeV sequences in these animals suggests that the virus has either undergone adaptive evolution to utilize pangolin-specific sialic acid variants or that the pangolin’s respiratory epithelium presents a permissive environment for the murine-adapted virus [1]. The study by Liu et al. utilized viral metagenomics to identify 68 viral contigs with high similarity to known viruses, with SeV and coronavirus being the dominant agents [1]. This is the first report of SeV in a non-rodent, non-primate mammal, and it raises the alarming possibility that SeV may have a much broader natural host range than previously appreciated. The implications for zoonotic risk are profound: if SeV can circulate in a wild, often trafficked mammal like the pangolin, it creates a new interface for human exposure. The pangolin trade, which involves close contact between humans and these animals in wet markets and during smuggling operations, provides a high-risk environment for spillover events. The World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) have repeatedly emphasized the role of wildlife markets as critical junctures for emerging infectious diseases, and the presence of SeV in this context warrants heightened surveillance.

Virome Surveillance: A Window into Viral Diversity and Emerging Threats

The application of unbiased viral metagenomics to wildlife populations has revolutionized our understanding of the global virome. The work on Malayan pangolins is a textbook example of this approach, revealing a hidden diversity of viruses that includes not only SeV but also coronaviruses, astroviruses, and parvoviruses [1]. The significance of this surveillance extends beyond mere cataloging. By identifying the viral communities present in a given host species, researchers can assess the potential for co-infections, recombination events, and the emergence of novel viral variants. For SeV, the co-detection with coronaviruses in pangolins is particularly concerning. Paramyxoviruses and coronaviruses share a similar respiratory tropism, and co-infection of a single host could theoretically facilitate recombination or the exchange of genetic modules, although this is less common for negative-sense RNA viruses like SeV. More importantly, the presence of SeV in a stressed, immunocompromised, and densely housed animal population (as occurs in trafficking networks) creates an ideal environment for viral evolution and adaptation.

The Centers for Disease Control and Prevention (CDC) and the Food and Agriculture Organization of the United Nations (FAO) have long advocated for a One Health approach to pandemic prevention, which integrates human, animal, and environmental health. Virome surveillance in wildlife is the cornerstone of this approach. The detection of SeV in pangolins should not be viewed as an isolated curiosity but as a sentinel event. It demonstrates that SeV, a virus long considered a “mouse virus,” has the ecological capacity to jump into novel mammalian orders. This finding necessitates a systematic expansion of surveillance efforts to other wildlife species, particularly those that are in frequent contact with humans, such as bats, rodents, and non-human primates. The fact that SeV is already used as a vaccine vector for human respiratory viruses (hPIV-1 and RSV) and is being tested in clinical trials further complicates the risk assessment [2, 12]. The widespread use of a replication-competent SeV-based vaccine in humans, even an attenuated one, could theoretically create a new selective pressure on the virus and potentially facilitate its adaptation to the human host. While current data indicate that the vaccine is safe and cleared rapidly in seropositive adults, the long-term ecological consequences of introducing a replicating SeV vector into the human population, even transiently, are not fully understood [2].

Implications for Public Health and Conservation

The zoonotic potential of SeV must be assessed through the lens of both public health and wildlife conservation. From a public health perspective, the risk of a pandemic originating from SeV is currently considered low, but not negligible. The virus’s inability to efficiently use human sialic acid receptors and the high prevalence of cross-reactive immunity to hPIV-1 in the human population are significant protective factors. However, the emergence of SARS-CoV-2 has taught us that host range predictions based on receptor tropism alone can be dangerously incomplete. A virus that can infect a wide range of mammals, as SeV appears to do, has more opportunities to acquire adaptive mutations. The defective viral genomes (DVGs) generated during SeV replication are a potent source of immunostimulatory RNA, but they also contribute to the heterogeneity of viral populations within a host [3, 9]. This heterogeneity, driven by the accumulation of DVGs, can lead to the selection of variants with altered pathogenicity or host range. The study by Genoyer and López demonstrated that cells enriched in DVGs are poor producers of viral particles but strong stimulators of innate immunity, while cells enriched in full-length genomes are the primary producers of infectious virus [3]. This functional heterogeneity within an infected host creates a complex evolutionary landscape where both standard and defective genomes are propagated, potentially allowing for the emergence of novel variants that could evade host immune responses or adapt to new receptors.

From a conservation standpoint, the detection of SeV in Malayan pangolins is a double-edged sword. On one hand, it provides a valuable data point for understanding the pathogens that threaten this critically endangered species. Pangolins are already under immense pressure from poaching and habitat loss, and the presence of a respiratory virus like SeV could contribute to morbidity and mortality in captive or stressed populations. On the other hand, the finding has been used by some to argue for increased culling or avoidance of these animals, which could be counterproductive to conservation efforts. The responsible approach, as advocated by the WOAH, is to use this information to improve biosecurity measures in rescue centers and to inform the safe handling of confiscated animals. The study by Liu et al. explicitly states that identifying and cataloguing the viruses carried by pangolins is a logical approach to evaluate the range of potential pathogens and help with conservation [1]. This sentiment underscores the dual purpose of virome surveillance: protecting human health and safeguarding endangered species.

The Role of Viral Vectors and the Risk of Accidental Introduction

A unique and often overlooked aspect of SeV’s zoonotic risk profile is its extensive use as a viral vector in gene therapy, vaccine development, and induced pluripotent stem cell (iPSC) reprogramming. The non-integrating, cytoplasmic replication of SeV makes it an attractive platform for delivering therapeutic genes, CRISPR/Cas9 components, and reprogramming factors [5, 6, 10, 14]. The SeV-based vaccine for RSV (SeVRSV) has already been tested in healthy adults and AGMs, demonstrating safety and immunogenicity [2, 12]. Furthermore, SeV vectors pseudotyped with other envelope proteins are being developed for gene therapy of cystic fibrosis, targeting the human airway epithelium with high efficiency [18]. While these applications are promising, they involve the deliberate introduction of replication-competent or replication-defective SeV into human populations or into the environment. The risk of a vaccine-derived SeV strain recombining with a wild-type strain circulating in wildlife, or of a laboratory escape, must be carefully managed. The development of defective and persistent SeV vectors (SeVdp), which are designed to be non-cytopathic and easily cleared by siRNA, represents a significant safety improvement [14]. However, the sheer volume of research involving SeV vectors, from oncolytic virotherapy in dogs to iPSC generation in humans, means that the virus is being handled in numerous laboratories worldwide, increasing the probability of accidental release [4, 7, 8, 11]. The oncolytic SeV therapy for canine mast cell tumors, for example, involves direct injection of live virus into dogs, creating a potential source of environmental contamination [4]. The CDC and national biosafety committees must therefore maintain rigorous oversight of all SeV-based research, particularly as the virus moves closer to clinical deployment.

In conclusion, the zoonotic potential of Sendai virus is not a static property but a dynamic function of its ecology, its molecular biology, and its increasing use in biomedical research. The discovery of SeV in Malayan pangolins has shattered the long-held assumption of strict murine host restriction, revealing a virus with a broader host range than previously imagined. While the immediate risk to human health remains low due to receptor incompatibility and pre-existing immunity, the virus’s capacity to infect a diverse array of mammals, its ability to generate immunostimulatory DVGs that drive evolutionary heterogeneity, and its widespread use as a human vaccine vector all converge to create a non-zero risk of future spillover or adaptation. Virome surveillance in wildlife, particularly in high-risk interface species like pangolins, is not merely an academic exercise; it is an essential component of a global early warning system for emerging infectious diseases. The data from Liu et al. [1] provide a critical piece of this puzzle, and they underscore the urgent need for expanded, coordinated surveillance efforts that integrate human, animal, and environmental health under the One Health umbrella.

References

[1] Liu P, Chen W, Chen J. Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica). Viruses. 2019. DOI: https://doi.org/10.3390/v11110979

[2] Huang FS, Bernstein D, Slobod K, Portner A, Takimoto T, Russell C, et al.. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Human Vaccines & Immunotherapeutics. 2020. DOI: https://doi.org/10.1080/21645515.2020.1779517

[3] Genoyer E, López C. Defective Viral Genomes Alter How Sendai Virus Interacts with Cellular Trafficking Machinery, Leading to Heterogeneity in the Production of Viral Particles among Infected Cells. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.01579-18

[4] Ilyinskaya G, Mukhina E, Soboleva AV, Matveeva O, Chumakov P. Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). Frontiers in Veterinary Science. 2018. DOI: https://doi.org/10.3389/fvets.2018.00116

[5] Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and biological sciences. 2009. DOI: https://doi.org/10.2183/pjab.85.348

[6] Park A, Hong P, Won ST, Thibault P, Vigant F, Oguntuyo KY, et al.. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Molecular Therapy: Methods & Clinical Development. 2016. DOI: https://doi.org/10.1038/mtm.2016.57

[7] Saga K, Kaneda Y. Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncolytic Virotherapy. 2015. DOI: https://doi.org/10.2147/OV.S66419

[8] Yang W, Mills J, Sullivan S, Liu Y, French D, Gadue P. iPSC Reprogramming from Human Peripheral Blood Using Sendai Virus Mediated Gene Transfer. Stembook. 2014. DOI: https://doi.org/10.3824/STEMBOOK.1.73.1

[9] Mercado-López X, Cotter C, Kim W, Sun Y, Muñoz L, Tapia K, et al.. Highly Immunostimulatory RNA Derived from a Sendai Virus Defective Viral Genome. Vaccine. 2013. DOI: https://doi.org/10.1016/j.vaccine.2013.09.040

[10] Nakanishi M, Otsu M. Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. Current Gene Therapy. 2012. DOI: https://doi.org/10.2174/156652312802762518

[11] Macarthur C, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, et al.. Generation of Human-Induced Pluripotent Stem Cells by a Nonintegrating RNA Sendai Virus Vector in Feeder-Free or Xeno-Free Conditions. Stem Cells International. 2012. DOI: https://doi.org/10.1155/2012/564612

[12] Jones B, Sealy R, Rudraraju R, Traina-Dorge V, Finneyfrock B, Cook A, et al.. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine. 2011. DOI: https://doi.org/10.1016/j.vaccine.2011.11.046

[13] Rudraraju R, Surman S, Jones B, Sealy R, Woodland D, Hurwitz J. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology. 2011. DOI: https://doi.org/10.1016/j.virol.2010.12.017

[14] Nishimura K, Sano M, Ohtaka M, Furuta B, Umemura Y, Nakajima Y, et al.. Development of Defective and Persistent Sendai Virus Vector. Journal of Biological Chemistry. 2010. DOI: https://doi.org/10.1074/jbc.M110.183780

[15] Chambers R, Takimoto T. Trafficking of Sendai Virus Nucleocapsids Is Mediated by Intracellular Vesicles. PLoS ONE. 2010. DOI: https://doi.org/10.1371/journal.pone.0010994

[16] Kast BWM, Bronkhorst AM, Waal LP, Melief CJ. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC- restricted and MHC-regulated; a model for MHC-disease associations. Journal of Experimental Medicine. 1986. DOI: https://doi.org/10.1084/jem.164.3.723

[17] Le TL, Mironova E, Garcin D, Compans R. Induction of Influenza-Specific Mucosal Immunity by an Attenuated Recombinant Sendai Virus. PLoS ONE. 2011. DOI: https://doi.org/10.1371/journal.pone.0018780

[18] Mitomo K, Griesenbach U, Inoue M, Somerton L, Meng C, Akiba E, et al.. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.. Molecular Therapy. 2010. DOI: https://doi.org/10.1038/mt.2010.13